GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 294 GBX 1.49% Market Closed
Market Cap: 52.8B GBX

Intrinsic Value

The intrinsic value of one GSK stock under the Base Case scenario is 1 663.39 GBX. Compared to the current market price of 1 294 GBX, GlaxoSmithKline PLC is Undervalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GSK Intrinsic Value
1 663.39 GBX
Undervaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
GlaxoSmithKline PLC

GSK
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for GSK cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

GlaxoSmithKline PLC
LSE:GSK
UK
Pharmaceuticals
Market Cap
53.6B GBX
IPO
May 22, 1972
UK
Pharmaceuticals
Market Cap
53.6B GBX
IPO
May 22, 1972
Price
gbxfalse
EPS
ÂŁfalse
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GSK?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about GlaxoSmithKline PLC
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
GlaxoSmithKline PLC

Current Assets 17B
Cash & Short-Term Investments 3.9B
Receivables 7.3B
Other Current Assets 5.8B
Non-Current Assets 42.5B
Long-Term Investments 1.2B
PP&E 10.1B
Intangibles 22.5B
Other Non-Current Assets 8.7B
Efficiency

Free Cash Flow Analysis
GlaxoSmithKline PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
GlaxoSmithKline PLC

Revenue
31.4B GBP
Cost of Revenue
-8.8B GBP
Gross Profit
22.6B GBP
Operating Expenses
-14.4B GBP
Operating Income
8.1B GBP
Other Expenses
-5.6B GBP
Net Income
2.6B GBP
Fundamental Scores

GSK Profitability Score
Profitability Due Diligence

GlaxoSmithKline PLC's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Free Cash Flow
Positive Operating Income
69/100
Profitability
Score

GlaxoSmithKline PLC's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

GSK Solvency Score
Solvency Due Diligence

GlaxoSmithKline PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Long-Term Solvency
Average D/E
Short-Term Solvency
46/100
Solvency
Score

GlaxoSmithKline PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GSK Price Targets Summary
GlaxoSmithKline PLC

Wall Street analysts forecast GSK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GSK is 1 685.95 GBX with a low forecast of 1 201.9 GBX and a high forecast of 2 782.5 GBX.

Lowest
Price Target
1 201.9 GBX
7% Downside
Average
Price Target
1 685.95 GBX
30% Upside
Highest
Price Target
2 782.5 GBX
115% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GSK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GSK Insider Trading
Buy and sell transactions by insiders

GSK News

Other Videos
What is the Intrinsic Value of one GSK stock?

The intrinsic value of one GSK stock under the Base Case scenario is 1 663.39 GBX.

Is GSK stock undervalued or overvalued?

Compared to the current market price of 1 294 GBX, GlaxoSmithKline PLC is Undervalued by 22%.

Back to Top